Andreas Gericke-von Skotnicki becomes managing director of PMG Presse-Monitor subsidiary X-CAGO
Berlin/Roermond – Andreas Gericke-von Skotnicki will assume the role of managing director of X-CAGO B.V, the Dutch specialist for data and content conversion in international publishing, from mid-August.

After more than a quarter of a century in his role, Koos Hussem, the founder and current managing director of X-CAGO, will relinquish management of the company to Andreas Gericke-von Skotnicki in the coming months before moving on to new tasks at the beginning of 2025.
“I am delighted that Andreas has opted to join us. He is a well-established part of the German-language publishing scene. With his knowledge, we can also establish X-CAGO as the leading provider of high-quality and fast data conversion for content producers in the D-A-CH region”, explains Koos Hussem.
Gericke-von Skotnicki is well versed in the publishing business. For more than a decade, he worked as a legal advisor for media law at the parent company of the Süddeutsche Zeitung. In 2019, he assumed responsibility for national and international licence marketing at the newspaper’s content marketer, DIZ München GmbH, where he has also been managing director since 2022.
“Particularly in the last six years as chairman of the general meeting of PMG, I have witnessed the great potential harboured by classic publishing content. Together with my colleagues from X-CAGO, I look forward to the challenges and opportunities that are also offered by the international content market”, says Andreas Gericke-von Skotnicki.
Ingo Kästner, managing director of X-CAGO´s parent company PMG Presse-Monitor, welcomes the new appointment: “With Andreas, we were able to find a true expert in publishing content. Together, we will develop the successful PMG and X-CAGO partnership into a full-service provider for publishers.”
He also extends his thanks to Koos Hussem: “Koos founded X-CAGO in 2000 and quickly brought it into the fast lane with his hands-on and optimistic approach. Thanks to his extraordinary commitment, the company has become one of the most sought-after providers of content management platforms and the conversion of publishing content on an international scale. Koos and his team have actively worked with us to closely integrate PMG and X-CAGO to both parties’ mutual benefit. This represents a solid foundation for further profitable growth, even in difficult times.”
Contacts
Roger DormeierMarketing | Communication | PRPMG Presse-Monitor GmbH & Co. KG
Tel:+49 30 28493 118roger.dormeier@presse-monitor.deImages

About PMG Presse-Monitor GmbH & Co. KG and X-CAGO B.V.
With the largest daily updated press database in the German-speaking world, PMG Presse-Monitor GmbH & Co. KG is a leading provider of digital media monitoring, press review creation and media analysis.
PMG markets the content and rights of around 900 newspaper and magazine publishers. Of over 4,000 print and online sources, around 3,000 are available digitally in the PMG press database. Based in Berlin, the company supplies over 5,000 customers from companies, associations, public institutions, media monitoring services and PR agencies.
Founded in 2001, PMG is a joint venture of German newspaper and magazine publishers with the shareholders Axel Springer, Frankfurter Allgemeine Zeitung, Gruner + Jahr, Handelsblatt Media Group, Hubert Burda Media, Spiegel-Verlag, Süddeutsche Zeitung as well as the Federal Association of Digital Publishers and Newspaper Publishers and the Media Association of the Free Press.
In 2021, PMG is taking a major step towards becoming a central data hub for content publishers with the acquisition of Dutch data converter X-CAGO B.V. The company is internationally successful in converting and standardising a wide variety of content formats. AchiveExpress, X-CAGO's digital archive solution, is used by publishers worldwide as a distribution platform for their content.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press Release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals. Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States. Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's
Growth and innovation as cornerstones of a strong democracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Pressmeddelande
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press Release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds25.4.2025 12:05:00 CEST | Pressmeddelande
- Picture is available at AP - Los Angeles/DNA - Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
DYMO® LETRATAG 200B VINNER DET PRESTIGEFYLLDA PRISET ”BUSINESS PRODUCT OF THE YEAR” - STRUKTURERAR OCH ORGANISERAR VARDAGEN24.4.2025 16:44:06 CEST | Press Release
Amsterdam – vikten av organisering, effektivitet och produktivitet i både personliga och professionella sammanhang har aldrig varit större. Detta då allt fler använder smarta lösningar för att förenkla sin vardag. DYMO®, en ledande leverantör av innovativa etikett- och utskriftslösningar, ligger här i framkant. Som ett erkännande har DYMO LetraTag 200B belönats med EOPA Best Business Product Award, en utmärkelse som lyfter fram hur den förenklat organisering både hemma och på kontoret. "Trenden mot smart självorganisering fortsätter", berättar Liesbet De Soomer, Global Marketing Director på DYMO. "LetraTag 200B stödjer utveckligen genom att erbjuda en användarvänlig lösning, som gör märkningen snabb och enkel. Med det här verktyget kan användaren strukturera vardagskaoset och organisera tillvaron.” EOPA Best Business Product Award, som delas ut årligen, uppmärksammar produkter som sticker ut för sitt nytänkande, sin funktionalitet och sin användarvänlighet. LetraTag 200B:s utmärkelse b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom